Utility of fecal lactoferrin in identifying crohn disease activity in children

Marian Pfefferkorn, James H. Boone, James T. Nguyen, Beth E. Juliar, Miriam A. Davis, Kelly K. Parker

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives: Fecal lactoferrin (FL) is a noninvasive biomarker that is elevated in Crohn disease (CD) compared to irritable bowel syndrome. The purpose of this study was to evaluate FL in identifying children with active versus inactive CD. Patients and Methods: Fresh stool samples were collected from children with CD scheduled for endoscopy or a clinic visit, and from new outpatients who were scheduled for colonoscopy. FL was determined using a polyclonal antibody-based enzyme-linked immunosorbent assay. Physical global assessment, endoscopic findings, erythrocyte sedimentation rate (ESR), and the Pediatric CD Activity Index (PCDAI) were recorded for patients with CD. The PCDAI scores symptoms, laboratory parameters, physical examination, and extraintestinal manifestations. A score of ≤10 is inactive disease, 11 to 30 is mild active, and ≤31 is moderate to severe active. Results: Of 101 study patients (4- to 20-year-old, 66 boys), 31 had active CD, 23 had inactive CD, and 37 had noninflammatory bowel disease (non- IBD) conditions. Four patients with ulcerative colitis and 6 patients with polyposis were excluded from analysis. FL was significantly elevated in CD versus non-IBD (P<0.001) and in active versus inactive CD (P<0.001). The PCDAI and ESR were higher in active CD than in inactive CD (both P<0.001). Using an FL cutoff of 7.25μg/g, FL has 100% sensitivity and 100% negative predictive value in detecting active CD. Using an FL cutoff level of 60mg/g, FL had 84% sensitivity, 74% specificity, 81% positive predictive value, and 77% negative predictive value for detecting active CD. Conclusions: FL is a promising biomarker of active CD and may be more practical to use when it is not feasible to obtain all of the necessary clinical information for the PCDAI.

Original languageEnglish
Pages (from-to)425-428
Number of pages4
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume51
Issue number4
DOIs
StatePublished - Oct 2010

Fingerprint

Lactoferrin
Crohn Disease
Blood Sedimentation
Pediatrics
Biomarkers
Irritable Bowel Syndrome
Colonoscopy
Ambulatory Care
Ulcerative Colitis
Endoscopy
Physical Examination
Outpatients

Keywords

  • Crohn disease
  • Irritable bowel syndrome
  • Lactoferrin
  • Pediatric inflammatory bowel disease

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health

Cite this

Utility of fecal lactoferrin in identifying crohn disease activity in children. / Pfefferkorn, Marian; Boone, James H.; Nguyen, James T.; Juliar, Beth E.; Davis, Miriam A.; Parker, Kelly K.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 51, No. 4, 10.2010, p. 425-428.

Research output: Contribution to journalArticle

Pfefferkorn, Marian ; Boone, James H. ; Nguyen, James T. ; Juliar, Beth E. ; Davis, Miriam A. ; Parker, Kelly K. / Utility of fecal lactoferrin in identifying crohn disease activity in children. In: Journal of Pediatric Gastroenterology and Nutrition. 2010 ; Vol. 51, No. 4. pp. 425-428.
@article{9fc667b502c54e91a8a18b703d9a668e,
title = "Utility of fecal lactoferrin in identifying crohn disease activity in children",
abstract = "Objectives: Fecal lactoferrin (FL) is a noninvasive biomarker that is elevated in Crohn disease (CD) compared to irritable bowel syndrome. The purpose of this study was to evaluate FL in identifying children with active versus inactive CD. Patients and Methods: Fresh stool samples were collected from children with CD scheduled for endoscopy or a clinic visit, and from new outpatients who were scheduled for colonoscopy. FL was determined using a polyclonal antibody-based enzyme-linked immunosorbent assay. Physical global assessment, endoscopic findings, erythrocyte sedimentation rate (ESR), and the Pediatric CD Activity Index (PCDAI) were recorded for patients with CD. The PCDAI scores symptoms, laboratory parameters, physical examination, and extraintestinal manifestations. A score of ≤10 is inactive disease, 11 to 30 is mild active, and ≤31 is moderate to severe active. Results: Of 101 study patients (4- to 20-year-old, 66 boys), 31 had active CD, 23 had inactive CD, and 37 had noninflammatory bowel disease (non- IBD) conditions. Four patients with ulcerative colitis and 6 patients with polyposis were excluded from analysis. FL was significantly elevated in CD versus non-IBD (P<0.001) and in active versus inactive CD (P<0.001). The PCDAI and ESR were higher in active CD than in inactive CD (both P<0.001). Using an FL cutoff of 7.25μg/g, FL has 100{\%} sensitivity and 100{\%} negative predictive value in detecting active CD. Using an FL cutoff level of 60mg/g, FL had 84{\%} sensitivity, 74{\%} specificity, 81{\%} positive predictive value, and 77{\%} negative predictive value for detecting active CD. Conclusions: FL is a promising biomarker of active CD and may be more practical to use when it is not feasible to obtain all of the necessary clinical information for the PCDAI.",
keywords = "Crohn disease, Irritable bowel syndrome, Lactoferrin, Pediatric inflammatory bowel disease",
author = "Marian Pfefferkorn and Boone, {James H.} and Nguyen, {James T.} and Juliar, {Beth E.} and Davis, {Miriam A.} and Parker, {Kelly K.}",
year = "2010",
month = "10",
doi = "10.1097/MPG.0b013e3181d67e8f",
language = "English",
volume = "51",
pages = "425--428",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Utility of fecal lactoferrin in identifying crohn disease activity in children

AU - Pfefferkorn, Marian

AU - Boone, James H.

AU - Nguyen, James T.

AU - Juliar, Beth E.

AU - Davis, Miriam A.

AU - Parker, Kelly K.

PY - 2010/10

Y1 - 2010/10

N2 - Objectives: Fecal lactoferrin (FL) is a noninvasive biomarker that is elevated in Crohn disease (CD) compared to irritable bowel syndrome. The purpose of this study was to evaluate FL in identifying children with active versus inactive CD. Patients and Methods: Fresh stool samples were collected from children with CD scheduled for endoscopy or a clinic visit, and from new outpatients who were scheduled for colonoscopy. FL was determined using a polyclonal antibody-based enzyme-linked immunosorbent assay. Physical global assessment, endoscopic findings, erythrocyte sedimentation rate (ESR), and the Pediatric CD Activity Index (PCDAI) were recorded for patients with CD. The PCDAI scores symptoms, laboratory parameters, physical examination, and extraintestinal manifestations. A score of ≤10 is inactive disease, 11 to 30 is mild active, and ≤31 is moderate to severe active. Results: Of 101 study patients (4- to 20-year-old, 66 boys), 31 had active CD, 23 had inactive CD, and 37 had noninflammatory bowel disease (non- IBD) conditions. Four patients with ulcerative colitis and 6 patients with polyposis were excluded from analysis. FL was significantly elevated in CD versus non-IBD (P<0.001) and in active versus inactive CD (P<0.001). The PCDAI and ESR were higher in active CD than in inactive CD (both P<0.001). Using an FL cutoff of 7.25μg/g, FL has 100% sensitivity and 100% negative predictive value in detecting active CD. Using an FL cutoff level of 60mg/g, FL had 84% sensitivity, 74% specificity, 81% positive predictive value, and 77% negative predictive value for detecting active CD. Conclusions: FL is a promising biomarker of active CD and may be more practical to use when it is not feasible to obtain all of the necessary clinical information for the PCDAI.

AB - Objectives: Fecal lactoferrin (FL) is a noninvasive biomarker that is elevated in Crohn disease (CD) compared to irritable bowel syndrome. The purpose of this study was to evaluate FL in identifying children with active versus inactive CD. Patients and Methods: Fresh stool samples were collected from children with CD scheduled for endoscopy or a clinic visit, and from new outpatients who were scheduled for colonoscopy. FL was determined using a polyclonal antibody-based enzyme-linked immunosorbent assay. Physical global assessment, endoscopic findings, erythrocyte sedimentation rate (ESR), and the Pediatric CD Activity Index (PCDAI) were recorded for patients with CD. The PCDAI scores symptoms, laboratory parameters, physical examination, and extraintestinal manifestations. A score of ≤10 is inactive disease, 11 to 30 is mild active, and ≤31 is moderate to severe active. Results: Of 101 study patients (4- to 20-year-old, 66 boys), 31 had active CD, 23 had inactive CD, and 37 had noninflammatory bowel disease (non- IBD) conditions. Four patients with ulcerative colitis and 6 patients with polyposis were excluded from analysis. FL was significantly elevated in CD versus non-IBD (P<0.001) and in active versus inactive CD (P<0.001). The PCDAI and ESR were higher in active CD than in inactive CD (both P<0.001). Using an FL cutoff of 7.25μg/g, FL has 100% sensitivity and 100% negative predictive value in detecting active CD. Using an FL cutoff level of 60mg/g, FL had 84% sensitivity, 74% specificity, 81% positive predictive value, and 77% negative predictive value for detecting active CD. Conclusions: FL is a promising biomarker of active CD and may be more practical to use when it is not feasible to obtain all of the necessary clinical information for the PCDAI.

KW - Crohn disease

KW - Irritable bowel syndrome

KW - Lactoferrin

KW - Pediatric inflammatory bowel disease

UR - http://www.scopus.com/inward/record.url?scp=78449245058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449245058&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e3181d67e8f

DO - 10.1097/MPG.0b013e3181d67e8f

M3 - Article

C2 - 20562721

AN - SCOPUS:78449245058

VL - 51

SP - 425

EP - 428

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 4

ER -